Metabolix, Inc. (NASDAQ: MBLX), an innovation-driven bioscience company focused on delivering sustainable solutions for plastics, chemicals and energy, today announced that the company has been awarded two new patents from the U.S. Patent and Trademark Office (PTO) related to the novel and efficient production of biobased polymers and industrial chemicals. U.S. Patent 8,093,022 titled “Polyhydroxalkanoate Biopolymer Compositions” enables production of a series of new PHA biopolymer compositions using genetically engineered microbial strains. U.S. Patent 8,114,643 titled “Polyhydroxalkanoate Production from Polyols” enables creation of genetic constructs to make the biobased chemical 3-hydroxypropionic acid in microbial and crop plant systems. It also describes the use of polyols, including glycerol and sugars, as alternate, renewable feedstocks. 3-Hydroxypropionic acid is useful for the production of PHA polymers and C3 chemicals including biobased acrylic acid, malonic acid, esters and amines. “We firmly believe that the pace of adoption of chemicals made from renewable resources will rapidly accelerate throughout this decade,” said Richard P. Eno, president and CEO of Metabolix. “The growing commitment from brand owners and consumers to produce and use ‘green’ products, combined with the rapid advances in biotechnology, means that our technology for producing biobased chemicals will be very well positioned to benefit from this trend.” “These recently issued patents highlight the breadth and depth of Metabolix's PHA technology platform . The recently issued patents describe a process that enables us to engineer microbes and plants to accumulate unique biobased monomers and PHA polymers inside their cells. The unique PHA polymers can then be extracted and used as bioplastics or converted directly from dried biomass using our FAST technology to chemical intermediates. In the case of the 3-hydoxypropionic acid polymer, using our FAST recovery technology results in the direct production of acrylic acid. We believe this approach will provide a significant advantage for creating cost-effective downstream recovery systems at commercial scale,” commented Oliver Peoples, an inventor on the patents and chief scientific officer of Metabolix. With more than 700 issued and pending patents, Metabolix has led the industry in the development of a family of biopolymers found in nature called PHAs (polyhydroxyalkanoates), including members of the PHA family. Metabolix is developing biobased industrial chemicals as “drop-in” replacements for petroleum-based products. In recent months, Metabolix has produced biobased gamma-Butyrolactone (“GBL,” a C4 chemical) at semi-works scale (60,000L) and has produced biobased acrylic acid (a C3 chemical) at lab scale. In the second quarter, Metabolix expects to begin sampling to prospective strategic partners dried biomass for conversion to biobased acrylic acid.
According to industry sources, the combined global market for conventional four-carbon (“C4”) and three-carbon (“C3”) industrial chemicals is estimated at more than $10 billion annually. C4 chemicals are used in applications ranging from high-performance engineering plastics to spandex. C3 chemicals have applications in paints, coatings, diapers and adhesives.About Metabolix Metabolix, Inc. is an innovation-driven bioscience company delivering sustainable solutions to the plastics, chemicals and energy industries. Metabolix is developing and commercializing Mirel TM and Mvera TM, a family of high-performance bioplastics which are biobased and biodegradable alternatives to many petroleum-based plastics. Metabolix’s biobased chemicals platform utilizes its novel “FAST” recovery process to enable the production of cost-effective, “drop-in” replacements for petroleum-based industrial chemicals. Metabolix is also developing a platform for co-producing plastics, chemicals and energy from crops. Metabolix has established an industry-leading intellectual property portfolio that, together with its knowledge of advanced industrial practice, provides a foundation for industry collaborations. For more information, please visit www.metabolix.com. (MBLX-G) Safe Harbor for Forward-Looking Statements This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding the ability to develop, commercialize and market biobased industrial chemicals, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated and are detailed in Metabolix's filings with the Securities and Exchange Commission, including its 10-K for the year ended December 31, 2011, which was filed on March 12, 2012. Metabolix assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.